EUCTR2007-004980-23-PT进行中（未招募）不适用
Double-Blind evaluation of the safety and efficacy of Quadriderme cream (betamethasone dipropionate, clotrimazole and gentamicin sulphate ) compare with betamethasone dipropionate combined with gentamicin sulphate and with betamethasone dipropionate in the treatment of Impetiginous Eczema.
Schering-Plough Farma, Lda.0 个研究点开始时间: 2007年11月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Mininum age 12 years old
- •Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema)
- •Diagnosis of impetiginous eczema.
- •Ability to understand the procedures of the protocol and follow the requirements during the course of the study.
- •Results of routine laboratory tests.
- •This results must all be within normal limits or not clinically relevant in order to be included in the trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnant patients or women of childbearing age who are not using birth control methods considered reliable by the attending physician.
- •Patients with history of hypersensitivity to any of the components of the medication being studied.
- •Patients in whom the extent or severity of the legions requires treatment of a different type than what is planned for this trial.
- •Patients who need anyother type of topical or systemic medications during the trial that might affect the course of the disease.
- •Patients who have been treated with other topical medication during the 14-day period prior to the start of the trial.
- •Patients who have received systemic corticosteroids or any other immunosuppressant medication suring the 28-day period prior to the start of the study.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised efficacy and safety study of taliglucerase alfa enzyme replacement therapy in children and adolescents with Gaucher disease (non-neuronopathic and chronic neuronopathic)Gaucher diseaseMedDRA version: 14.1Level: PTClassification code 10018048Term: Gaucher's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-000498-42-Outside-EU/EEAProtalix Biotherapeutics10
已完成
不适用
A Randomized, Double-Blind Safety and Efficacy Study of Losartan Plus Hydrochlorothiazide Versus Losartan as First-Line Therapy After 6 Weeks in Patients With Severe Hypertensio-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-055-00MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay bone fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.MedDRA version: 14.1Level: PTClassification code 10021067Term: HypopituitarismSystem Organ Class: 10014698 - Endocrine disordershypopituitarismEUCTR2012-001183-30-Outside-EU/EEAemours Children's Clinic53
进行中（未招募）
1 期
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertensioprimary or secondary hypertensionMedDRA version: 20.0 Level: LLT Classification code 10036695 Term: Primary hypertension System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10039834 Term: Secondary hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2014-000674-18-BGArbor Pharmaceuticals, LLC.260
进行中（未招募）
1 期
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertensioprimary or secondary hypertensionMedDRA version: 17.1Level: LLTClassification code 10036695Term: Primary hypertensionSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 17.1Level: PTClassification code 10039834Term: Secondary hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2014-000674-18-ITArbor Pharmaceuticals, LLC.215